Hikma launches Deflazacort Tablets. Hikma stock sits 12.23 percent below its high

Published on 10/15/2026 at 14:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Hikma reported USD 1.73 billion revenue in the first half of 2026, up 4.20 percent. Hikma stock costs EUR 19.47 on October 15, 2026.

Product launch and earnings context

Hikma reported USD 1.73 billion revenue in the first half of 2026, up 4.20 percent.
Hikma launched Deflazacort Tablets in the US on October 14, 2026.
Hikma stock trades at EUR 19.47 at 1:47 p.m. CEST at Lang & Schwarz on October 15, 2026.
Citi set a GBp 1,810 price target on October 13, 2026.
Hikma had a GBP 3.4 billion market capitalization on October 15, 2026.

Fotorealistische sterile Pharma-Produktionslinie mit Injektionsfläschchen und Edelstahlanlagen — Hikma Pharmaceuticals PLC GB00B128J450 zeigt moderne Injektions-Produktionslinie in sterilem Pharmawerk mit Edelstahlanlagen, Illustration mit AI erstellt.

Hikma (ISIN GB00B0LCW083) launched Deflazacort Tablets in the US on October 14, 2026, according to Hikma. The product announcement gives the stock a fresh company-specific event after a period dominated by earnings and analyst updates.

Revenue growth sets the base

Hikma reported revenue of USD 1.73 billion for the first half of 2026, an increase of 4.20 percent from the first half of 2025, while net income was USD 223.0 million, down 6.30 percent year over year, according to Simply Wall St. The mixed result matters because revenue growth has not translated into higher reported earnings.

Hikma's own investor materials said the Branded segment grew revenue 15.00 percent in the first half of 2026 and that full-year 2026 guidance was reiterated. The same materials describe Injectables, Branded and Hikma Rx as the group's three operating segments.

Three dates define the sequence

Hikma launched Glucentra in Saudi Arabia on September 16, 2026, appointed Rebecca Hall as chief financial officer on September 24, 2026, and launched Deflazacort Tablets in the US on October 14, 2026.

What does the R&D plan mean?

The next investor-facing milestone is an R&D seminar on October 20, 2026, followed by a trading update on November 5, 2026. Hikma said it aims to allocate 5.00 percent to 6.00 percent of revenue to R&D, with the seminar series covering respiratory, nasal, semi-solids and liquids, solid orals, and injectables, according to Hikma.

Analyst expectations remain higher than the London quote. Citi lowered its target to GBp 1,810 from GBp 1,870 on October 13, 2026 and kept a Buy rating, as reported by Markets Insider. MarketBeat listed a GBp 2,085.83 average target from six analysts on October 15, 2026, with a consensus Buy rating.

Stock price and valuation

Hikma stock was trading at EUR 19.47 at Lang & Schwarz on October 15, 2026 at 1:47 p.m. CEST. On the LSE, the stock was last at GBp 1,637 at 12:57 p.m. BST on October 15, 2026, while its 52-week range was GBp 1,187 to GBp 1,865. Its market capitalization was GBP 3.4 billion on October 15, 2026.

The further course of trading is shown by the continuously updated real-time quote of Hikma stock.